CRISPR/Cas9 therapeutics for liver diseases

Rajagopal N. Aravalli, Clifford J. Steer

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The development of innovative genome editing techniques in recent years has revolutionized the field of biomedicine. Among the novel approaches, the clustered regularly interspaced short palindromic repeat/CRISPR-associated protein (CRISPR/Cas9) technology has become the most popular, in part due to its matchless ability to carry out gene editing at the target site with great precision. With considerable successes in animal and preclinical studies, CRISPR/Cas9-mediated gene editing has paved the way for its use in human trials, including patients with a variety of liver diseases. Gene editing is a logical therapeutic approach for liver diseases because many metabolic and acquired disorders are caused by mutations within a single gene. In this review, we provide an overview on current and emerging therapeutic strategies for the treatment of liver diseases using the CRISPR/Cas9 technology.

Original languageEnglish (US)
Pages (from-to)4265-4278
Number of pages14
JournalJournal of Cellular Biochemistry
Issue number6
StatePublished - Jun 2018


  • gene editing
  • gene therapy
  • liver, non-viral vectors
  • viral vectors


Dive into the research topics of 'CRISPR/Cas9 therapeutics for liver diseases'. Together they form a unique fingerprint.

Cite this